ZURA BIO LTD (ZURA)
KYG9TY5A1016 - Common Stock
ZURA Stock Earnings: Zura Bio Beats EPS for Q2 2024
ZURA stock results show that Zura Bio beat analyst estimates for earnings per share the second quarter of 2024.
Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
Zura Bio Announces Robert Lisicki as CEO and Director
Redx to Quit London Stock Exchange’s AIM, Citing Low Liquidity
Biotech company Redx Pharma Plc is set to pull its shares from the London Stock Exchange’s smallest market, citing liquidity constraints and saying it will attract investors more easily as a private company.
ZURA Stock Earnings: Zura Bio Misses EPS for Q4 2023
ZURA stock results show that Zura Bio missed analyst estimates for earnings per share the fourth quarter of 2023.
ZURA Stock Earnings: Zura Bio Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Zura Bio (NASDAQ:ZURA) just reported results for the fourth quarter of 2023.Zur...
Zura Bio Announces Participation at March Conferences
Zura Bio Announces Participation at February Investor Conferences
Zura Bio appoints industry veteran Robert Lisicki as President and COO (NASDAQ:ZURA)
Zura Bio (NASDAQ:ZURA) has appointed Robert Lisicki as President and Chief Operating Officer.Mr.
Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO
Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit
Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok
Relative Strength Alert For Zura Bio
Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors
Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights
Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute
Oppenheimer starts Zura Bio at outperform, cites potential of ZB-106 (NASDAQ:ZURA)
Oppenheimer has initiated coverage of Zura Bio (ZURA) with an outperform rating, citing the revenue potential of its drug ZB-106, also known as tibulizumab. Read more here.
Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Zura Bio to join Russell 2000 and Russell 3000 indexes (NASDAQ:ZURA)
Zura Bio (ZURA) to be added to the Russell 2000 and Russell 3000 Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on...
Zura Bio to Join the Russell 2000® and Russell 3000® Indexes
Why Shares of Zura Bio Climbed Tuesday
The biotech stock continued its rise in June.
Wednesday Sector Laggards: Grocery & Drug Stores, Biotechnology Stocks
TIO Stock Alert: Hindenburg Short Report Slams Tingo Group
Tingo Group (TIO) stock is taking a beating on Tuesday after the company was hit with a short report from Hindenburg Research.
MKC Stock Alert: BofA Double-Upgrades McCormick Shares
McCormick (MKC) stock is extra spicy on Tuesday after the company got a double upgrade from Bank of America analyst Peter Galbo.